Is the Combination of Pharmacokinetic and Pharmacodynamic Monitoring of Infliximab-Treated Patients the Way Forward?

Queiroz, Natália Sousa Freitas; Charabaty, Aline

doi:10.1016/j.cgh.2020.02.029

Cited by 4 publications

(2 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This creates unique opportunities to expand knowledge in the field of IBD and to grow a provider's network and reach. For example, the authors of this manuscript, an IBD fellow, a gastropsychologist, and an IBD specialist, connected on Twitter over IBD-centric conversations and found themselves to be a good fit to collaborate [19]. Fellows and junior faculty now have the opportunity to make a positive social media impression and connect with mentors across institutions and countries.…”

Section: The Physician Perspectivementioning

confidence: 98%

Social media in inflammatory bowel disease: the patient and physician perspective

Ahmed

Taft

Charabaty

2021

Current Opinion in Gastroenterology

Self Cite

View full text Add to dashboard Cite

Purpose of reviewSocial media use by patients with inflammatory bowel disease (IBD) and their respective providers continues to increase, promoting disease awareness and scholarship. In this review article, we summarize the current literature regarding social media use and IBD, discuss both the patient and physician perspective, and provide guidance to avoid commonly encountered pitfalls.Recent findingsPatients and providers commonly rely on social media to share medical information, advocate for improved IBD care, and to network and collaborate on common research interests. This shift from more traditional formats of education and networking continues to grow exponentially, and even more rapidly so during the COVID-19 pandemic.SummarySocial media use in the IBD community will continue to grow and lead to further innovation. Providers should be aware of social media as a valuable tool for their patients and themselves.

show abstract

Section: The Physician Perspectivementioning

confidence: 98%

Social media in inflammatory bowel disease: the patient and physician perspective

Ahmed

Taft

Charabaty

2021

Current Opinion in Gastroenterology

Self Cite

View full text Add to dashboard Cite

show abstract

“…AC: There are a few studies in favor of proactive TDM for TNFi, with the idea that optimizing TNFi levels at induction & early during therapy is key to optimizing long term outcomes. 11 The prospective PANTS study suggests that TNFi levels at induction affect long term outcomes in CD, with low IFX or ADA levels at week 14 being associated with non-remission at week 54, and IFX levels>7 mcg/mL or ADA levels> 12 mcg/mL at week 14 being both associated with clinical remission at week 54, respectively (Figure 4). 12 for q4wks vs q8wks maintenance regimen).…”

Section: Ar: Q2: When Starting a Patient On Vdz Do You Routinely Check A Trough Level During The Induction Of Therapy? What Level Do You mentioning

confidence: 99%

Do pharmacokinetics justify dose-optimization for loss of response to Vedolizumab in IBD?

2021

Self Cite

View full text Add to dashboard Cite

Knowledge surrounding therapeutic drug monitoring (TDM) in inflammatory bowel disease is growing, especially for tumor necrosis factor-? inhibitors class of drugs. Yet, TDM for the ?4?7 integrin antibody vedolizumab (VDZ) has not been equally established, as real-life data on VDZ pharmacokinetics, VDZ drug level and treatment response are scarce. We summarize the @GIJournal discussion held on July 14, 2021 during which the article by Ungar et al. “Dose-optimization for loss-of-response to vedolizumab - pharmacokinetics and immune mechanisms” was critically reviewed by our expert Dr. Aline Charabaty (AC), and moderated by Dr. Asad ur Rahman (AR).

show abstract

Reply

Dreesen

Vermeire

2020

Clinical Gastroenterology and Hepatology

View full text Add to dashboard Cite

Is the Combination of Pharmacokinetic and Pharmacodynamic Monitoring of Infliximab-Treated Patients the Way Forward?

Cited by 4 publications

References 6 publications

Social media in inflammatory bowel disease: the patient and physician perspective

Social media in inflammatory bowel disease: the patient and physician perspective

Do pharmacokinetics justify dose-optimization for loss of response to Vedolizumab in IBD?

Reply

Contact Info

Product

Resources

About